{"type":"trials","record":{"id":42230,"source_id":"clinicaltrials-gov","external_id":"NCT05105607","title":"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy Participants","brief_summary":"The primary objective of this study is to evaluate the safety and tolerability of D-4517.2 after single subcutaneous (SC) doses in healthy participants.","overall_status":"Completed","phases":["PHASE1"],"study_type":"INTERVENTIONAL","sponsor":"Ashvattha Therapeutics, Inc.","enrollment":16,"countries":["Australia"],"start_date":"2022-01-11","completion_date":"2022-08-31","last_update_date":"2022-09-21","source_url":"https://clinicaltrials.gov/study/NCT05105607","editorial_summary":"A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"18 Years to 65 Years","comparator":null,"organization":"Ashvattha Therapeutics, Inc.","interventions":["D-4517.2"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Number of Participants With Adverse Events — Day 1 up to Day 15","Maximum Plasma Concentration (Cmax) of D-4517.2 — Day 1 up to Day 3","Time to Maximum Plasma Concentration (tmax) of D-4517.2 — Day 1 up to Day 3","Apparent Terminal Rate Constant (kel) of D-4517.2 — Day 1 up to Day 3","Apparent Elimination Half-life (t1/2) of D-4517.2 — Day 1 up to Day 3","Area Under the Concentration-time Curve Based On the Last Measurable Concentration (AUC0-t) — Day 1 up to Day 3","Area Under the Concentration-time Curve from Time Zero to Infinity (AUC0-inf) — Day 1 up to Day 3","Clearance (CL) of D-4517.2 — Day 1 up to Day 3"],"design_description":"NON RANDOMIZED · PARALLEL · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Neovascular Age-related Macular Degeneration","Diabetic Macular Edema","D-4517.2"],"relevance_confidence":60,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05105607","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2022-01-11 to 2022-08-31","comparator":null,"confidence":"structured-source","population":"ALL · 18 Years to 65 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.938Z","intervention":["D-4517.2"],"participants":16,"study_design":"NON RANDOMIZED · PARALLEL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Number of Participants With Adverse Events — Day 1 up to Day 15","Maximum Plasma Concentration (Cmax) of D-4517.2 — Day 1 up to Day 3","Time to Maximum Plasma Concentration (tmax) of D-4517.2 — Day 1 up to Day 3","Apparent Terminal Rate Constant (kel) of D-4517.2 — Day 1 up to Day 3","Apparent Elimination Half-life (t1/2) of D-4517.2 — Day 1 up to Day 3","Area Under the Concentration-time Curve Based On the Last Measurable Concentration (AUC0-t) — Day 1 up to Day 3","Area Under the Concentration-time Curve from Time Zero to Infinity (AUC0-inf) — Day 1 up to Day 3","Clearance (CL) of D-4517.2 — Day 1 up to Day 3"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Source terminology supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["controlled terminology","controlled context","study type"],"relevance_score":60,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42230","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}